AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37194394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 37194394 — intervention group
Group type: EXPERIMENTAL
Intervention: Brepocitinib 30 mg and 60 mg once daily
Number of subjects: 218
Study 37194432 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnographic (PSG)-based sleep disturbances
Number of subjects: 131
Study 37194458 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hyper-polypharmacy (greater than or equal to 10 medications)
Number of subjects: 55997
Study 37194458 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative polypharmacy (5-9 medications)
Number of subjects: 55997
Study 37194458 — intervention group
Group type: COMPARATOR
Intervention: Non-polypharmacy (fewer than 5 medications)
Number of subjects: 55997
Study 37194458 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hyper-polypharmacy
Number of subjects: 55997
Study 37194458 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative polypharmacy
Number of subjects: 55997
Study 37194458 — intervention group
Group type: COMPARATOR
Intervention: Non-polypharmacy
Number of subjects: 55997
Study 37194458 — intervention group
Group type: COMPARATOR
Intervention: Patients not exposed to polypharmacy
Number of subjects: 55997
Study 37194458 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients exposed to preoperative polypharmacy
Number of subjects: 55997
Study 37194488 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 1.5 mg/kg intravenous infusion, administered 15 minutes prior to surgery
Number of subjects: 12
Study 37194618 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Garments (CG) combined with Physiotherapy (PT)
Number of subjects: 36
Study 37194618 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 36
Study 37194813 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium intensity coughing technique during subcutaneous low molecular weight heparin injection
Number of subjects: 100
Study 37194813 — intervention group
Group type: COMPARATOR
Intervention: Standard injection technique
Number of subjects: 100
Study 37194964 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP)
Number of subjects: 92
Study 37195023 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201
Number of subjects: 0
Study 37195023 — intervention group
Group type: EXPERIMENTAL
Intervention: paxalisib
Number of subjects: 0
Study 37195023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ONC201 and paxalisib
Number of subjects: 0
Study 37195063 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) + Methotrexate (MTX)
Number of subjects: 2761
Study 37195063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Methotrexate (MTX)
Number of subjects: 2761
Study 37195128 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI combined with chemotherapy
Number of subjects: 211
Study 37195128 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 211
Study 37195144 — intervention group
Group type: EXPERIMENTAL
Intervention: NightWatch intervention for nocturnal seizure detection
Number of subjects: 53
Study 37195144 — intervention group
Group type: EXPERIMENTAL
Intervention: NightWatch intervention
Number of subjects: 53
Study 37195370 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive assessment of myocardial PD-L1 expression
Number of subjects: 0
Study 37195407 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 2 weeks (LEBQ2W)
Number of subjects: 1720
Study 37195407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1720
Study 37195407 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dose of lebrikizumab (All-LEB)
Number of subjects: 1720
Study 37195423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy after ultra-short-pulse glucocorticoids (GCs)
Number of subjects: 18
Study 37195518 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance tongue exercise using pressure sensors for 12 weeks with usual care
Number of subjects: 19
Study 37195518 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 19
Study 37195666 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate practice intervention (3 weekly, 30-minute video-conferenced sessions with personalized feedback)
Number of subjects: 72
Study 37195666 — intervention group
Group type: COMPARATOR
Intervention: Usual care (passive control)
Number of subjects: 72
Study 37195667 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-RT with concurrent and consolidated oral S-1 chemotherapy (CRTCT group)
Number of subjects: 330
Study 37195667 — intervention group
Group type: COMPARATOR
Intervention: SIB-RT alone (RT group)
Number of subjects: 330
Study 37195676 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Department process improvement package with a focus on collaborative safety planning
Number of subjects: 2761
Study 37195787 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective extended dissection (SED)
Number of subjects: 520
Study 37195787 — intervention group
Group type: COMPARATOR
Intervention: Standard dissection (SD)
Number of subjects: 520
Study 37195906 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumpstart intervention (stigma focused counseling)
Number of subjects: 177
Study 37195906 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 177
Study 37195906 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumpstart intervention (for participants 30 and older)
Number of subjects: 177
Study 37195924 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) strategy using Health Scouts
Number of subjects: 1903
Study 37195941 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg of peresolimab
Number of subjects: 0
Study 37195941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37195942 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside
Number of subjects: 266
Study 37195999 — intervention group
Group type: EXPERIMENTAL
Intervention: PfRAS vaccination
Number of subjects: 0
Study 37195999 — intervention group
Group type: COMPARATOR
Intervention: Noninfectious mosquito bites (mock vaccination)
Number of subjects: 0
Study 37196017 — intervention group
Group type: EXPERIMENTAL
Intervention: Kato-Katz
Number of subjects: 5000
Study 37196017 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-FLOTAC
Number of subjects: 5000
Study 37196017 — intervention group
Group type: EXPERIMENTAL
Intervention: FECPAKG2
Number of subjects: 5000
Study 37196017 — intervention group
Group type: EXPERIMENTAL
Intervention: Kato-Katz with NS survey design
Number of subjects: 5000
Study 37196017 — intervention group
Group type: COMPARATOR
Intervention: WHO recommended SS survey design
Number of subjects: 5000
Study 37196061 — intervention group
Group type: EXPERIMENTAL
Intervention: PXVX0317 vaccine
Number of subjects: 0
Study 37196069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy (hFSRT) combined with 1500 mg Durvalumab on day 5, followed by infusions every 4 weeks for up to 12 months.
Number of subjects: 6
Study 37196069 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated stereotactic radiotherapy (hFSRT)
Number of subjects: 6
Study 37196158 — intervention group
Group type: EXPERIMENTAL
Intervention: 9MW2821
Number of subjects: 0
Study 37196158 — intervention group
Group type: COMPARATOR
Intervention: Enfortumab vedotin (EV)
Number of subjects: 0
Study 37196396 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment for OSAS
Number of subjects: 40
Study 37196396 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization with a reward system
Number of subjects: 40
Study 37196396 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved communication with medical team and equipment company
Number of subjects: 40
Study 37196396 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of visual supports and social support for education
Number of subjects: 40
Study 37196404 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning information provision by general practitioners (GPs)
Number of subjects: 25
Study 37196404 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning discussions involving GPs and/or relatives
Number of subjects: 25
Study 37196404 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators of ACP discussions
Number of subjects: 25
Study 37196404 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to ACP discussions
Number of subjects: 25
Study 37196421 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 0
Study 37196421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37196527 — intervention group
Group type: EXPERIMENTAL
Intervention: Metarrestin (ML-246) administered orally at a dose of 1 mg
Number of subjects: 0
Study 37196637 — intervention group
Group type: EXPERIMENTAL
Intervention: Social deprivation
Number of subjects: 0
Study 37196637 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37196799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygenation target (8 kPa)
Number of subjects: 335
Study 37196799 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygenation target (12 kPa)
Number of subjects: 335
Study 37197707 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive approach (intra-arrest transport with in-hospital ECPR initiation)
Number of subjects: 286
Study 37197707 — intervention group
Group type: COMPARATOR
Intervention: Standard ACLS
Number of subjects: 286
Study 37197785 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III OI
Number of subjects: 37
Study 37197785 — intervention group
Group type: EXPERIMENTAL
Intervention: Type IV OI
Number of subjects: 37
Study 37197785 — intervention group
Group type: EXPERIMENTAL
Intervention: Type VI OI
Number of subjects: 37
Study 37197785 — intervention group
Group type: EXPERIMENTAL
Intervention: General OI population
Number of subjects: 37
Study 37197808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of medical and allied healthcare professional (AHP) staff
Number of subjects: 138
Study 37197808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of support staff
Number of subjects: 138
Study 37197808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of AHP support
Number of subjects: 138
Study 37197841 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS)
Number of subjects: 24
Study 37197845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 462
Study 37197904 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorised spiral enteroscopy (MSE)
Number of subjects: 125
Study 37197904 — intervention group
Group type: COMPARATOR
Intervention: Single-balloon enteroscopy (SBE)
Number of subjects: 125
Study 37197905 — intervention group
Group type: EXPERIMENTAL
Intervention: Test, treat, retest and re-treat initial treatment failures
Number of subjects: 15057
Study 37197905 — intervention group
Group type: EXPERIMENTAL
Intervention: Family members of a positive index case
Number of subjects: 15057
Study 37197909 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTE-ACS with left circumflex (LCx) occlusion
Number of subjects: 4412
Study 37197909 — intervention group
Group type: COMPARATOR
Intervention: NSTE-ACS with right coronary artery (RCA) occlusion
Number of subjects: 4412
Study 37197909 — intervention group
Group type: COMPARATOR
Intervention: NSTE-ACS with left anterior descending coronary artery (LAD) occlusion
Number of subjects: 4412
Study 37197909 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTE-ACS with total coronary occlusion (TCO)
Number of subjects: 4412
Study 37198021 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 booster dose
Number of subjects: 150
Study 37198160 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated clinical decision support system (alert group)
Number of subjects: 5060
Study 37198160 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 5060
Study 37198293 — intervention group
Group type: EXPERIMENTAL
Intervention: Longuette™ chimney stent-graft for left subclavian artery revascularization
Number of subjects: 34
Study 37198293 — intervention group
Group type: EXPERIMENTAL
Intervention: Longuette™ chimney stent-graft
Number of subjects: 34
Study 37198558 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based stereoptic serious games
Number of subjects: 30
Study 37198558 — intervention group
Group type: COMPARATOR
Intervention: Refractive correction
Number of subjects: 30
Study 37198558 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched healthy individuals)
Number of subjects: 30
Study 37198562 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high intensity physical activity program (45 min, 3 times per week, lasting 12 weeks)
Number of subjects: 0
Study 37198562 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 37198670 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week e-health intervention following a 2-week brisk-walking training
Number of subjects: 184
Study 37198670 — intervention group
Group type: COMPARATOR
Intervention: 12-week conventional behavioural change intervention following a 2-week brisk-walking training
Number of subjects: 184
Study 37198686 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib
Number of subjects: 0
Study 37198687 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game 'Broodles' played over a period of 4 weeks
Number of subjects: 154
Study 37198687 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 154
Study 37199326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab combined with quad-shot radiotherapy (14.8 Gy in four twice-daily fractions)
Number of subjects: 15
Study 37199326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 15
Study 37199326 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad-shot radiotherapy
Number of subjects: 15
Study 37199401 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat intake (≥4 servings/wk)
Number of subjects: 2293
Study 37199401 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume intake (≥4 servings/wk)
Number of subjects: 2293
Study 37199401 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-sourced iron intake (highest quartile)
Number of subjects: 2293
Study 37199401 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary iron and overall plant-sourced iron intake
Number of subjects: 2293
Study 37199424 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 82
Study 37199424 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 82
Study 37199427 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal tenofovir disoproxil fumarate-based antiretroviral treatment (mART)
Number of subjects: 400
Study 37199427 — intervention group
Group type: COMPARATOR
Intervention: Infant nevirapine prophylaxis (iNVP)
Number of subjects: 400
Study 37199438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Fracture Injection (HiFI) - multimodal local injection of bupivacaine, morphine sulfate, ketorolac at the fracture site during surgery
Number of subjects: 184
Study 37199438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HiFI)
Number of subjects: 184
Study 37199438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Fracture Injection (HiFI)
Number of subjects: 184
Study 37199436 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress ball during endoscopy (n = 30)
Number of subjects: 60
Study 37199436 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 60
Study 37199608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Number of subjects: 0
Study 37199608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate
Number of subjects: 0
Study 37199608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37199745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR) 600 mg/m
Number of subjects: 16
Study 37199745 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fenretinide plus safingol
Number of subjects: 16
Study 37199775 — intervention group
Group type: EXPERIMENTAL
Intervention: Target walking task
Number of subjects: 15
Study 37199775 — intervention group
Group type: COMPARATOR
Intervention: Normal walking task
Number of subjects: 15
Study 37199775 — intervention group
Group type: EXPERIMENTAL
Intervention: Various walking speeds (0.3 m/s, 0.5 m/s, 0.9 m/s, and preferred)
Number of subjects: 15
Study 37199775 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability assessment
Number of subjects: 15
Study 37199789 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI-deficient granulocytes ≤ 5% at baseline
Number of subjects: 2813
Study 37199789 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI-deficient granulocytes > 30% at baseline
Number of subjects: 2813
Study 37199789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 2813
Study 37199789 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal pain
Number of subjects: 2813
Study 37199884 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 6 mg BID, titrated to 12 mg BID if necessary, later replaced by 15/30 mg once-daily extended-release equivalents
Number of subjects: 493
Study 37199921 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental reminiscing training
Number of subjects: 44
Study 37199921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 37199932 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood Family Check-Up (FCU) intervention
Number of subjects: 0
Study 37199932 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37199977 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSE Theatre (Experimental group)
Number of subjects: 290
Study 37199977 — intervention group
Group type: COMPARATOR
Intervention: Active Control Condition (Tackling Teenage Training, TTT)
Number of subjects: 290
Study 37200022 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus trifluridine-tipiracil
Number of subjects: 62
Study 37200022 — intervention group
Group type: COMPARATOR
Intervention: Trifluridine-tipiracil alone
Number of subjects: 62
Study 37200022 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus trifluridine-tipiracil (subgroup with ctDNA analysis)
Number of subjects: 62
Study 37200037 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 870
Study 37200037 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification cataract surgery (PCS)
Number of subjects: 870
Study 37200067 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook advertisement campaign
Number of subjects: 70
Study 37200067 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment cost
Number of subjects: 70
Study 37200547 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Social Work and Self-Care (MBSWSC) programme
Number of subjects: 62
Study 37200547 — intervention group
Group type: COMPARATOR
Intervention: Active control (modified mindfulness-based programme)
Number of subjects: 62
Study 37200720 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined position (head elevations of 0°, 10°, 18°, and 28°)
Number of subjects: 35
Study 37200720 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 35
Study 37200903 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 57
Study 37200903 — intervention group
Group type: COMPARATOR
Intervention: Music Listening (ML)
Number of subjects: 57
Study 37200944 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy-dense oral nutritional supplement (edONS, 2.4 kcal/mL)
Number of subjects: 103
Study 37200944 — intervention group
Group type: COMPARATOR
Intervention: Reference oral nutritional supplement (heONS, 2.0 kcal/mL)
Number of subjects: 103
Study 37200972 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinocardiography (KCG) technology
Number of subjects: 30
Study 37200972 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal LVEF ≥50%)
Number of subjects: 30
Study 37200995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 634
Study 37201078 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel combined with LBP and tegafur
Number of subjects: 10
Study 37201155 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-task deep learning (DL) radiomic model incorporating liquid biopsy (LB) parameters including circulating tumor cell (CTC) features.
Number of subjects: 0
Study 37201155 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy (LB) technique using circulating tumor cell (CTC) parameters.
Number of subjects: 0
Study 37201438 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered, individualized, and self-directed gait modification with weekly telerehabilitation appointments and remote monitoring
Number of subjects: 20
Study 37201438 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group (wait period before intervention)
Number of subjects: 20
Study 37201510 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-8-secreting CD4 T cells
Number of subjects: 0
Study 37201510 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 0
Study 37201510 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell profile
Number of subjects: 0
Study 37201546 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Sequential Bilateral Cataract Surgery (ISBCS)
Number of subjects: 865
Study 37201546 — intervention group
Group type: COMPARATOR
Intervention: Delayed Sequential Bilateral Cataract Surgery (DSBCS)
Number of subjects: 865
Study 37201747 — intervention group
Group type: EXPERIMENTAL
Intervention: M-TAPA (40 ml 0.25% bupivacaine)
Number of subjects: 60
Study 37201747 — intervention group
Group type: EXPERIMENTAL
Intervention: M-TAPA
Number of subjects: 60
Study 37201747 — intervention group
Group type: COMPARATOR
Intervention: Control (surgical infiltration)
Number of subjects: 60